First PhIII data show once-weekly omarigliptin as good as daily Januvia
This article was originally published in Scrip
Executive Summary
Merck & Co's first Phase III data from its once-weekly DPP-4 inhibitor omarigliptin showed it works as well as the company's successful once-daily diabetes drug Januvia (sitagliptin). Merck is working towards a first filing in Japan by year-end.